The 36-month beta value for NVCR is at 0.71. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for NVCR is 97.51M, and currently, shorts hold a 6.39% of that float. The average trading volume for NVCR on September 20, 2024 was 1.36M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVCR) stock’s latest price update
NovoCure Ltd (NASDAQ: NVCR)’s stock price has plunge by -2.83relation to previous closing price of 17.84. Nevertheless, the company has seen a -6.65% plunge in its stock price over the last five trading sessions. businesswire.com reported 2024-09-09 that ROOT, Switzerland–(BUSINESS WIRE)—- $NVCR–Novocure to Present Real-World Data at ESMO 2024.
NVCR’s Market Performance
NovoCure Ltd (NVCR) has seen a -6.65% fall in stock performance for the week, with a -0.94% decline in the past month and a -9.10% plunge in the past quarter. The volatility ratio for the week is 5.89%, and the volatility levels for the past 30 days are at 6.70% for NVCR. The simple moving average for the past 20 days is -2.76% for NVCR’s stock, with a 4.83% simple moving average for the past 200 days.
Analysts’ Opinion of NVCR
Many brokerage firms have already submitted their reports for NVCR stocks, with JP Morgan repeating the rating for NVCR by listing it as a “Neutral.” The predicted price for NVCR in the upcoming period, according to JP Morgan is $15 based on the research report published on November 20, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVCR reach a price target of $25, previously predicting the price at $85. The rating they have provided for NVCR stocks is “Neutral” according to the report published on August 28th, 2023.
Piper Sandler gave a rating of “Overweight” to NVCR, setting the target price at $45 in the report published on August 08th of the previous year.
NVCR Trading at -6.78% from the 50-Day Moving Average
After a stumble in the market that brought NVCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.92% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 5.89%, as shares surge +2.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.30% lower at present.
During the last 5 trading sessions, NVCR fell by -5.82%, which changed the moving average for the period of 200-days by +34.64% in comparison to the 20-day moving average, which settled at $17.85. In addition, NovoCure Ltd saw 16.11% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCR starting from Cordova Ashley, who sale 688 shares at the price of $20.14 back on Aug 02 ’24. After this action, Cordova Ashley now owns 219,179 shares of NovoCure Ltd, valued at $13,857 using the latest closing price.
VERNON W ANTHONY, the Director of NovoCure Ltd, sale 964 shares at $23.89 during a trade that took place back on Jun 04 ’24, which means that VERNON W ANTHONY is holding 164,833 shares at $23,033 based on the most recent closing price.
Stock Fundamentals for NVCR
Current profitability levels for the company are sitting at:
- -0.34 for the present operating margin
- 0.76 for the gross margin
The net margin for NovoCure Ltd stands at -0.31. The total capital return value is set at -0.18. Equity return is now at value -43.40, with -14.23 for asset returns.
Based on NovoCure Ltd (NVCR), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.09. The debt to equity ratio resting at 2.02. The interest coverage ratio of the stock is -20.19.
Currently, EBITDA for the company is -176.66 million with net debt to EBITDA at -3.92. When we switch over and look at the enterprise to sales, we see a ratio of 4.33. The receivables turnover for the company is 8.5for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.46.
Conclusion
In conclusion, NovoCure Ltd (NVCR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
